THROMBOSIS RESEARCH 67; 643-654,1992 0049-3848/92 $5.00 + .OOPrinted in the USA. Copyright (c) 1992 Pergamon Press Ltd. All rights reserved.
COAGULATION
AND FIBRINOLYTIC SYSTEM IMPAIRMENT DEPENDENT DIABETES MELLITUS
IN INSULIN
Franco Cannassi, Marco Morale, Renzo Puccetti, Ferdinando De Negri, Fabio Monzani, Renzo Navalesi and Giuliano Mariani. Institute of 2nd Medical Clinic, University of Pisa, 56126 Pisa, Italy. (Received 16.4.1992; accepted in revised form 17.7.1992 by Editor M.B. Donati) (Received by Executive Editorial Office 20.8.1992)
ABSTRACT Selected coagulation and fibrinolytic parameters were assessed in 40 insulin dependent diabetes mellitus patients with varying degrees of metabolic control; 30 healthy subjects matched for age and sex formed the control group. Activated Partial Thromboplastin Time, Prothrombin Time, Fibrinogen, Factor VII, Antithrombin 111,Protein C, Plasminogen, a2-Plasmin Inhibitor, Plasminogen Activator Inhibitor- 1, tissue-Plasminogen Activator were functionally evaluated. Antigenic levels of tissue-Plasminogen Activator, Thrombin-Antithrombin complexes and fibrinolytic specific product BP 15-42 were also determined. Compared to the control group diabetic patients displayed significantly higher levels of Fibrinogen (p
COAGULATION
AND FIBRINOLYTIC SYSTEM IMPAIRMENT DEPENDENT DIABETES MELLITUS
IN INSULIN
Franco Cannassi, Marco Morale, Renzo Puccetti, Ferdinando De Negri, Fabio Monzani, Renzo Navalesi and Giuliano Mariani. Institute of 2nd Medical Clinic, University of Pisa, 56126 Pisa, Italy. (Received 16.4.1992; accepted in revised form 17.7.1992 by Editor M.B. Donati) (Received by Executive Editorial Office 20.8.1992)
ABSTRACT Selected coagulation and fibrinolytic parameters were assessed in 40 insulin dependent diabetes mellitus patients with varying degrees of metabolic control; 30 healthy subjects matched for age and sex formed the control group. Activated Partial Thromboplastin Time, Prothrombin Time, Fibrinogen, Factor VII, Antithrombin 111,Protein C, Plasminogen, a2-Plasmin Inhibitor, Plasminogen Activator Inhibitor- 1, tissue-Plasminogen Activator were functionally evaluated. Antigenic levels of tissue-Plasminogen Activator, Thrombin-Antithrombin complexes and fibrinolytic specific product BP 15-42 were also determined. Compared to the control group diabetic patients displayed significantly higher levels of Fibrinogen (p
![[Coagulation and fibrinolytic system in the vascular risks diabetes mellitus and hyperlipoproteinemia (author's transl)].](/assets/img/hold.png)
